Comerica Bank Sells 36,467 Shares of The Cooper Companies, Inc. $COO

Key Points

• Comerica Bank reduced its holdings in The Cooper Companies, Inc. by 47.0% during the first quarter, now owning 41,092 shares valued at approximately $3.47 million.
• Cooper Companies reported $1.10 earnings per share (EPS) for the most recent quarter, exceeding analysts' expectations of $1.07, and had a revenue of $1.06 billion.
• Several research analysts have downgraded their price targets for Cooper Companies, with JPMorgan cutting it to $66.00 and Stifel Nicolaus to $85.00, while the consensus rating remains a "Moderate Buy".

Comerica Bank reduced its position in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 47.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 41,092 shares of the medical device company's stock after selling 36,467 shares during the period. Comerica Bank's holdings in Cooper Companies were worth $3,466,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Zions Bancorporation National Association UT purchased a new position in shares of Cooper Companies in the 1st quarter worth approximately $33,000. City Holding Co. bought a new stake in Cooper Companies during the first quarter worth $34,000. GKV Capital Management Co. Inc. purchased a new position in Cooper Companies in the first quarter worth $40,000. Larson Financial Group LLC grew its stake in Cooper Companies by 1,071.0% in the 1st quarter. Larson Financial Group LLC now owns 726 shares of the medical device company's stock valued at $61,000 after purchasing an additional 664 shares during the period. Finally, HM Payson & Co. increased its position in shares of Cooper Companies by 147.4% during the 1st quarter. HM Payson & Co. now owns 893 shares of the medical device company's stock valued at $75,000 after purchasing an additional 532 shares during the last quarter. 24.39% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Cooper Companies news, EVP Brian G. Andrews bought 1,525 shares of the business's stock in a transaction that occurred on Tuesday, September 2nd. The stock was purchased at an average cost of $65.68 per share, with a total value of $100,162.00. Following the completion of the acquisition, the executive vice president owned 22,191 shares in the company, valued at $1,457,504.88. This trade represents a 7.38% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Daniel G. Mcbride acquired 3,000 shares of the company's stock in a transaction on Tuesday, September 2nd. The shares were purchased at an average cost of $65.04 per share, with a total value of $195,120.00. Following the completion of the purchase, the chief operating officer directly owned 63,120 shares of the company's stock, valued at $4,105,324.80. This trade represents a 4.99% increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 1.98% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Wall Street Zen downgraded shares of Cooper Companies from a "buy" rating to a "hold" rating in a report on Saturday, July 12th. Stifel Nicolaus lowered their price objective on Cooper Companies from $90.00 to $85.00 and set a "buy" rating on the stock in a research report on Thursday, August 28th. Loop Capital set a $100.00 target price on shares of Cooper Companies in a research report on Tuesday, June 17th. Mizuho dropped their target price on shares of Cooper Companies from $105.00 to $90.00 and set an "outperform" rating for the company in a research report on Wednesday, July 16th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Cooper Companies from $76.00 to $66.00 and set a "neutral" rating for the company in a report on Thursday, August 28th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $86.64.

Cooper Companies Stock Up 2.8%

Cooper Companies stock traded up $1.81 during trading hours on Wednesday, hitting $67.14. The stock had a trading volume of 3,823,719 shares, compared to its average volume of 2,285,719. The stock's 50-day moving average price is $72.13 and its 200-day moving average price is $77.06. The company has a quick ratio of 1.23, a current ratio of 2.12 and a debt-to-equity ratio of 0.29. The stock has a market capitalization of $13.35 billion, a P/E ratio of 33.07, a price-to-earnings-growth ratio of 1.63 and a beta of 0.97. The Cooper Companies, Inc. has a 12-month low of $61.78 and a 12-month high of $112.38.

Cooper Companies (NASDAQ:COO - Get Free Report) last issued its quarterly earnings data on Wednesday, August 27th. The medical device company reported $1.10 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.03. Cooper Companies had a net margin of 10.08% and a return on equity of 9.82%. The firm had revenue of $1.06 billion for the quarter, compared to analysts' expectations of $1.06 billion. During the same quarter in the prior year, the business earned $0.96 EPS. The business's quarterly revenue was up 5.7% on a year-over-year basis. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. Equities research analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.